CF
ACRS icon

Cantor Fitzgerald’s Aclaris Therapeutics ACRS Stock Holding History

Cantor Fitzgerald’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-451,120
Closed -$641K – 368
2025
Q2 		$641K Sell
451,120
-244,453
-35% -$331K 0.01% 198
2025
Q1 		$1.06M Buy
695,573
+595,573
+596% +$1.27M 0.02% 112
2024
Q4 		$248K Buy
+100,000
New +$249K ﹤0.01% 165

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cantor Fitzgerald's ACRS Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Aclaris Therapeutics (ACRS) in Q3 2025, closing a stake of 451,120 shares — an estimated $641K sold.

Cantor Fitzgerald first reported a position in ACRS in Q4 2024 and held it in 3 quarters. The position peaked at $1.06M in Q1 2025. 103 funds tracked by Wall St. Rank hold ACRS as of Q3 2025.

  • Cantor Fitzgerald reported no remaining Aclaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 451,120 Aclaris Therapeutics shares in Q3 2025, an estimated $641K.
  • Cantor Fitzgerald first reported a position in Aclaris Therapeutics in Q4 2024 and held it in 3 quarters.
  • Cantor Fitzgerald's Aclaris Therapeutics position peaked at $1.06M in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.